Morinidazole

Research use only, not for human use.

Morinidazole shows antibacterial activity and can be used in studies about bacterial infections research such as appendicitis and pelvic inflammatory disease caused by anaerobic bacteria.

Morinidazole shows antibacterial activity and can be used in studies about bacterial infections research such as appendicitis and pelvic inflammatory disease caused by anaerobic bacteria.(In Vitro):Morinidazole shows antibacterial activity against Trichomonas vaginalis and Entamoeba histolytica with MICs of 2 and 3 μg/mL.(In Vivo):Morinidazole (20 and 25 mg/kg; p.o.) inhibits Trichomonas vaginalis and Entamoeba histolytica in vivo. In the renal failure model in SD rats, Morinidazole (50 mg/kg; i.v.) shows a higher concentration in the liver, plasma, and kidney than lung, spleen, and heart.

Morinidazole can be metabolized to N+-glucuronide of S-morinidazole [M8-1] and N+-glucuronide of R-morinidazole [M8-2] via N+-glucuronidation, and sulfate conjugate of morinidazole [M7] via sulfation.M7 is a substrate for organic anion transporter 1 (OAT1) and OAT3 (Km=28.6 and 54.0 μM, respectively), M8-1 and M8-2 are the substrates for OAT3.Morinidazole shows activity against Trichomonas vaginalis and Entamoeba histolytica in vitro, with MIC values of 2 μg/mL and 3 μg/mL, respectively.

Morinidazole (20 mg/kg or 25 mg/kg; p.o.; single dose) inhibits Trichomonas vaginalis and Entamoeba histolytica in vivo in rats with EC50s of 20 mg/kg and 25 mg/kg, respectively.Morinidazole (50 mg/kg; i.v.; 0.25, 0.75, 1.5 h) shows a different concentration in tissues after intravenous injection, with a higher concentration in liver, kidney, plasma than lung, heart, and spleen in mice.Pharmacokinetic parameters of Morinidazole in control and 5/6 nephrectomized (Nx) rats.Intravenous injection; 50 mg/kg Morinidazole; Blood samples were collected from retro-orbital venous plexus before the dose (0 hours), at 5, 15, and 30 minutes, and at 1, 2, 4, 6, 8, and 12 hours after the dose. Animal Model:Renal failure model in SD rats (180-220 g)Dosage:50 mg/kg Administration:Intravenous injection; sacrificed rats at 0.25, 0.75, and 1.50 hours after dose administration Result:Increased plasma exposures slightly compared with control.

——

GPCR/G Protein

Antibacterial

——

——

——

92478-27-8

270.289

C11H18N4O4

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (369.97 mM)

Cc1ncc(n1CC(O)CN1CCOCC1)[N+]([O-])=O

——

(-20℃)

With Ice Pack

≥ 2 years